Saturday, 19 May 2012

Companies Profiles

Title Filter 
Display # 
# Article Title Author Hits
1 Elan Corporation, plc (ADR) EPS Growth for next year hanged about 157.10% - NYSE:ELN Tapebeat Staff 628
2 Advanced Battery Technologies, Inc. generated Return on Assets of 19.06% with no Debt in most recent quarter - NASDAQ:ABAT Tapebeat Staff 497
3 OFIRMEV’s Europe Track Record, A Good Omen for US Market, Cadence Pharmaceuticals (CADX) Venkat Nukala 4086
4 Why Linjeta Could Revolutionize Diabetes Care, Biodel (NASDAQ: BIOD) Joseph Krueger 6332
5 Transparent, Profitable and Working Hard Under the Radar (PINK:UYMG) Stephen Ramey 950
6 Affymax Not Nearly as Anemic as Investors Feel (NASDAQ:AFFY) Joseph Krueger 1890
7 Cash is the King in Myriad Pharma (NASDAQ:MYRX) Joseph Krueger 1639
8 Undoubtedly The Busiest Stock Ahead of ASCO Conference, Exelixis, Inc. (NASDAQ:EXEL) Venkat Nukala 1565
9 Biodel's VIAject May Push Mannkind's Afrezza Aside (BIOD, MNKD) Joseph Krueger 4810
10 CytRx: All That Glitters Could Be Bright Gold (NASDAQ:CYTR) Joseph Krueger 1631
11 Antigenics Oncophage Well Ahead of Dendreon (NASDAQ:AGEN) Joseph Krueger 12685
12 A Big Bet Placed On Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Joseph Krueger 5721
13 TapeBeat's Analysis on Delcath System, Inc. (Nasdaq:DCTH) Stephen Ramey 2505
14 NASDAQ:APPA - A.P. Pharma Receives FDA Complete Response Letter for APF530 TapeBeat Staff 760
15 NASDAQ:APPA - Analysis of APF530 With An Upcoming PDUFA Stephen Ramey and Philip Runfeldt 1132
16 PROLOR Biotech (PBTH): A Solution to Big Pharma’s Problems Joseph Krueger 936
17 Poniard Pharmaceuticals: Oversold, Undervalued, and Poised for a Short Squeeze Jospeh Krueger 1868
18 Applied Neurosolutions (APSN)- the next ATHX? Jospeh Krueger 1014
19 Genelink (GNLK) - Pharmacogenomics, Nutragenetics and Dermagenetics: Big Words for Big Revenues Jospeh Krueger 1446
20 TapeBeat has Best Annualized Returns Dr Phil 897

Page 1 of 2

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Banner